{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:54:46Z","timestamp":1769086486598,"version":"3.49.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":3411,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T00:00:00Z","timestamp":1474070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>There are limited data on the effect of low-dose, intermittent inotropic therapy in an outpatient setting on the quality of life (QOL) in patients with advanced refractory heart failure (HF) symptoms. We aimed to analyse the effect of this treatment modality on QOL and subsequent survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The study population comprised 287 consecutive patients with advanced refractory HF symptoms who were treated with low-dose, intravenous intermittent inotropic therapy in the HF Day Care Service at Sheba Medical Centre between September 2000 and September 2012. All patients completed a baseline Minnesota Living with Heart Failure Questionnaire (MLWHFQ), and 137 (48%) completed a 1\u2009year follow-up questionnaire. MLWHFQ scores' means ranged from 0 (better QOL) to 5 (worse QOL). Mean age was 68\u2009\u00b1\u200912, 86% were men, 77% had ischaemic cardiomyopathy, and the mean left ventricle ejection fraction (LVEF) was 26%\u2009\u00b1\u200913. The mean baseline MLWHFQ score was 3.1 (\u00b11), while the mean at 1\u2009year of treatment was of 2.7 (\u00b11.1), indicating an overall improvement in QOL associated with intermittent low-dose inotrope therapy (p\u2009&amp;lt;\u20090.01). Multivariate analysis showed that younger age, non-ischaemic cardiomyopathy, and worse renal function were independently associated with improvement in QOL at 1\u2009year. Improvement in QOL was not associated with a significant survival benefit during subsequent follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with advanced refractory HF symptoms, treatment with low-dose, intermittent intravenous inotropes in an outpatient setting is associated with significant improvement in QOL. However, improvement in QOL in this population does not appear to affect subsequent long-term survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12114","type":"journal-article","created":{"date-parts":[[2016,9,18]],"date-time":"2016-09-18T00:15:24Z","timestamp":1474157724000},"page":"122-129","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Quality of Life and Long-Term Mortality in Patients with Advanced Chronic Heart Failure Treated with Intermittent Low-Dose Intravenous Inotropes in an Outpatient Setting"],"prefix":"10.1093","volume":"4","author":[{"given":"Fernando","family":"Chernomordik","sequence":"first","affiliation":[{"name":"Heart Failure Institute, Heart Centre, Sheba Medical Centre and Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dov","family":"Freimark","sequence":"additional","affiliation":[{"name":"Heart Failure Institute, Heart Centre, Sheba Medical Centre and Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Arad","sequence":"additional","affiliation":[{"name":"Heart Failure Institute, Heart Centre, Sheba Medical Centre and Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Shechter","sequence":"additional","affiliation":[{"name":"Heart Failure Institute, Heart Centre, Sheba Medical Centre and Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shlomi","family":"Matetzky","sequence":"additional","affiliation":[{"name":"Heart Failure Institute, Heart Centre, Sheba Medical Centre and Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Savir","sequence":"additional","affiliation":[{"name":"Heart Failure Institute, Heart Centre, Sheba Medical Centre and Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Shlomo","sequence":"additional","affiliation":[{"name":"The Israeli Association for Cardiovascular Trials , Tel Hashomer ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Peled","sequence":"additional","affiliation":[{"name":"Clalit Health Services , Central Region ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"Heart Failure Institute, Heart Centre, Sheba Medical Centre and Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"The Israeli Association for Cardiovascular Trials , Tel Hashomer ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Peled","sequence":"additional","affiliation":[{"name":"Heart Failure Institute, Heart Centre, Sheba Medical Centre and Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,9,17]]},"reference":[{"key":"2026012115132522700_ehf212114-bib-0001","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012115132522700_ehf212114-bib-0002","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","article-title":"Clinical epidemiology of heart failure","volume":"93","author":"Mosterd","year":"2007","journal-title":"Heart"},{"key":"2026012115132522700_ehf212114-bib-0003","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejheart.2007.04.003","article-title":"Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology","volume":"9","author":"Metra","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026012115132522700_ehf212114-bib-0004","first-page":"1","article-title":"The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"2026012115132522700_ehf212114-bib-0005","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJM199812173392503","article-title":"Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure","volume":"339","author":"Cohn","year":"1998","journal-title":"N Engl J Med"},{"key":"2026012115132522700_ehf212114-bib-0006","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(96)10488-8","article-title":"Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure: Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators","volume":"349","author":"Hampton","year":"1997","journal-title":"Lancet"},{"key":"2026012115132522700_ehf212114-bib-0007","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"2026012115132522700_ehf212114-bib-0008","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/hrt.76.3.223","article-title":"Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial","volume":"76","author":"Lubsen","year":"1996","journal-title":"Heart"},{"key":"2026012115132522700_ehf212114-bib-0009","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/eurheartj\/ehp338","article-title":"Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials","volume":"30","author":"Metra","year":"2009","journal-title":"Eur Heart J"},{"key":"2026012115132522700_ehf212114-bib-0010","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00134-010-2113-0","article-title":"Clinical presentation, management and outcomes in the acute heart failure global survey of standard treatment (ALARM-HF)","volume":"37","author":"Follath","year":"2011","journal-title":"Intensive Care Med"},{"key":"2026012115132522700_ehf212114-bib-0011","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group; long-term use of a left ventricular assist device for end-stage heart failure","volume":"345","author":"Rose","year":"2001","journal-title":"New Engl J Med"},{"key":"2026012115132522700_ehf212114-bib-0012","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0002-8703(86)90475-8","article-title":"Intermittent ambulatory dobutamine therapy in patients with severe congestive heart failure","volume":"112","author":"Krell","year":"1986","journal-title":"Am Heart J"},{"key":"2026012115132522700_ehf212114-bib-0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06902-9","article-title":"Cardiovascular and renal actions of dopamine. Potential clinical application","volume":"241","author":"Goldberg","year":"1972","journal-title":"Pharmacol Rev"},{"key":"2026012115132522700_ehf212114-bib-0014","first-page":"419","article-title":"An advanced chronic heart failure day care service: a 5 year single-center experience","volume":"11","author":"Freimark","year":"2009","journal-title":"Isr Med Assoc J"},{"key":"2026012115132522700_ehf212114-bib-0015","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0002-8703(92)90986-6","article-title":"Assessment of Patient Outcome with the Minnesota Living with Heart Failure Questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan","volume":"124","author":"Rector","year":"1992","journal-title":"Am Heart J"},{"key":"2026012115132522700_ehf212114-bib-0016","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1015547713061","article-title":"Discriminant properties of commonly used quality of life measures in heart failure","volume":"11","author":"Bennett","year":"2002","journal-title":"Qual Life Res"},{"key":"2026012115132522700_ehf212114-bib-0017","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/0002-9149(93)90575-W","article-title":"For the SOLVD Investigators. Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) trial quality-of-life substudy","volume":"71","author":"Gorkin","year":"1993","journal-title":"Am J Cardiol"},{"key":"2026012115132522700_ehf212114-bib-0018","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.CIR.82.3.774","article-title":"Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group","volume":"82","author":"Uretsky","year":"1990","journal-title":"Circulation"},{"issue":"suppl. II","key":"2026012115132522700_ehf212114-bib-0019","first-page":"138","article-title":"Intermittent dobutamine in ambulatory out-patients with chronic cardiac failure","volume":"74","author":"Dies","year":"1986","journal-title":"Circulation"},{"key":"2026012115132522700_ehf212114-bib-0020","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2014.01.016","article-title":"Inotropes","volume":"63","author":"Francis","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"2026012115132522700_ehf212114-bib-0021","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/0167-5273(90)90149-Y","article-title":"Placebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatment","volume":"28","author":"Dubourg","year":"1990","journal-title":"Int J Cardiol"},{"key":"2026012115132522700_ehf212114-bib-0022","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1056\/NEJM199307153290301","article-title":"Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone study group","volume":"329","author":"Feldman","year":"1993","journal-title":"New Engl J Med"},{"key":"2026012115132522700_ehf212114-bib-0023","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S0735-1097(84)80189-8","article-title":"Amrinone in the treatment of chronic cardiac failure","volume":"3","author":"Likoff","year":"1984","journal-title":"J Am Coll Cardiol"},{"key":"2026012115132522700_ehf212114-bib-0024","doi-asserted-by":"crossref","first-page":"75C","DOI":"10.1016\/0002-9149(87)90531-5","article-title":"Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation","volume":"60","author":"Khalife","year":"1987","journal-title":"Am J Cardiol"},{"key":"2026012115132522700_ehf212114-bib-0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/IJGM.S62549","article-title":"Inotropes do not increase mortality in advanced heart failure","volume":"7","author":"Guglin","year":"2014","journal-title":"Int J Gen Med"},{"key":"2026012115132522700_ehf212114-bib-0026","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.118","article-title":"Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial","volume":"16","author":"Altenberger","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012115132522700_ehf212114-bib-0027","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0002-8703(80)90226-4","article-title":"Long-term benefit of dobutamine in patients with congestive cardiomyopathy","volume":"100","author":"Unverferth","year":"1980","journal-title":"Am Heart J"},{"key":"2026012115132522700_ehf212114-bib-0028","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0002-8703(98)70352-7","article-title":"Beneficial effects of intermittent home administration of the inotrope\/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study","volume":"135","author":"Cesario","year":"1998","journal-title":"Am Heart J"},{"key":"2026012115132522700_ehf212114-bib-0029","first-page":"195","article-title":"Intermittent dobutamine hydrochloride infusions in outpatients with chronic congestive heart failure","volume":"4","author":"Roffman","year":"1985","journal-title":"Clin Pharm"},{"key":"2026012115132522700_ehf212114-bib-0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/clc.4960270107","article-title":"Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes","volume":"27","author":"L\u00f3pez-Candales","year":"2004","journal-title":"Clin Cardiol"},{"key":"2026012115132522700_ehf212114-bib-0031","first-page":"129","article-title":"Symptomatic improvement in patients treated with intermittent infusion of inotropes: a double-blind placebo controlled pilot study","volume":"33","author":"L\u00f3pez-Candales","year":"2002","journal-title":"J Med"},{"key":"2026012115132522700_ehf212114-bib-0032","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012115132522700_ehf212114-bib-0033","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0735-1097(03)00185-2","article-title":"Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission and functional decline","volume":"41","author":"Smith","year":"2003","journal-title":"J Am Coll Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12114","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/4\/2\/122\/66224980\/eschf_4_2_122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/4\/2\/122\/66224980\/eschf_4_2_122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:18:12Z","timestamp":1769026692000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/4\/2\/122\/8413075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,17]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,9,17]]},"published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12114","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5]]},"published":{"date-parts":[[2016,9,17]]},"assertion":[{"value":"2016-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}